Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely used for the treatment of T2DM and promote weight loss in individuals with obesity, have demonstrated significant cardiovascular benefits. Here, GLP1R is linked to type 2 diabetes mellitus.